Foundation Medicine, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Therapeutic and Diagnostic Methods for Cancer (US 11,674,962) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Methods of Treating Cancer (US 11,725,247) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Methods of treating cholangiocarcinoma (US 11,771,698) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Sep 29, 2027The maintenance fee for Novel KIF5B-RET Fusion Molecules and Uses Thereof (US 9,297,011) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Multigene Analysis of Tumor Samples (US 11,959,141) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
- 1 fee due Nov 17, 2027The maintenance fee for Optimization of Multigene Analysis of Tumor Samples (US 9,340,830) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,118,213 | Optimization of Multigene Analysis of Tumor Samples In force · Low confidence | In force | Low confidence | |
| US 11,136,619 | Optimization of Multigene Analysis of Tumor Samples In force · Low confidence | In force | Low confidence | |
| US 11,421,265 | Optimization of Multigene Analysis of Tumor Samples In force · Low confidence | In force | Low confidence | |
| US 12,180,540 | Optimization of Multigene Analysis of Tumor Samples In force · Low confidence | In force | Low confidence | |
| US 9,297,011 | Novel KIF5B-RET Fusion Molecules and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,884,060 | Novel KIF5B-RET Fusion Molecules and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 9,340,830 | Optimization of Multigene Analysis of Tumor Samples In force · High confidence | In force | High confidence | |
| US 10,093,983 | Novel Estrogen Receptor Mutations and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,286,532 | Novel Estrogen Receptor Mutations and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 12,116,638 | Novel Estrogen Receptor Mutations and Uses Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 43: 6 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
62 pending · 13 abandoned · 24 no status recorded